Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of cabazitaxel in AR-V7-positive metastatic castration-resistant prostate cancer
NL-OMON47078Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2017
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Erasmus MC. Primary endpoint: PSA response. Started Feb 2017; status: active, not recruiting.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON47078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47078.